The rise in BioSante Pharmaceuticals (BPAX -13.2%) is attributable to frenzied day trading of a...

|By:, SA News Editor

The rise in BioSante Pharmaceuticals (BPAX -13.2%) is attributable to frenzied day trading of a new momo favorite, according to biotech analyst Adam Feuerstein. He also remains underwhelmed with the FDA approval the company landed for its testosterone-boosting gel given that 5 competing products are already in the market. Despite today's selloff, BPAX is on a +67.6% YTD bender.